Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Operating Expenses (2019 - 2023)

Alx Oncology Holdings' Operating Expenses history spans 5 years, with the latest figure at $48.0 million for Q4 2023.

  • For Q4 2023, Operating Expenses rose 49.05% year-over-year to $48.0 million; the TTM value through Dec 2023 reached $170.3 million, up 33.62%, while the annual FY2025 figure was $104.0 million, 26.99% down from the prior year.
  • Operating Expenses for Q4 2023 was $48.0 million at Alx Oncology Holdings, down from $53.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $53.3 million in Q3 2023 and bottomed at $4.3 million in Q3 2019.
  • The 5-year median for Operating Expenses is $24.6 million (2021), against an average of $23.4 million.
  • The largest annual shift saw Operating Expenses skyrocketed 150.55% in 2021 before it increased 8.84% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $8.9 million in 2019, then skyrocketed by 99.25% to $17.8 million in 2020, then skyrocketed by 59.73% to $28.5 million in 2021, then increased by 13.16% to $32.2 million in 2022, then skyrocketed by 49.05% to $48.0 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Operating Expenses are $48.0 million (Q4 2023), $53.3 million (Q3 2023), and $36.8 million (Q2 2023).